Pure Global AI
ISRCTN14220944

Proton beam therapy in patients with breast cancer: evaluating early and late effects

PARABLE: Proton beam therapy in patients with breast cancer: evaluating early and late effects
Institute of Cancer ResearchISRCTN Registryother
VerifiedISRCTN Registry
Study focus
Disease/Condition
Malignant neoplasm of breast
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Institute of Cancer Research
Funder
NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR131120
Location
United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Nov 27, 2019
End date
Feb 01, 2030
Enrollment
192 participants
Summary

PARABLE aims to show that proton beam therapy (PBT) reduces the predicted risk of late serious heart toxicity with no increase in other shorter-term side effects compared with tailored photon radiotherapy (intensity‐modulated arc therapy). PARABLE's specific objectives are to: 1. Change international practice for breast PBT early with a primary outcome analysis at 2 years' follow-up 2. Improve the understanding of PBT biological models through a mechanistic study with potential benefit for all cancer patients needing PBT.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastPersonal history of malignant neoplasm of breast
Data source
Registry
ISRCTN Registry
Trial ID
ISRCTN14220944
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for ISRCTN14220944 through Pure Global AI's free database. This phase not specified trial is sponsored by Institute of Cancer Research and is currently status unknown. The study focuses on Malignant neoplasm of breast. Target enrollment is 192 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ISRCTN Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.